To delineate a possible mechanism in which FBXL7 upregulation triggers PTX resistance in ovarian cancer, we next performed an in silico computational simulation using Ingenuity Pathway Analysis (IPA) software to identify potentially activated or inhibited upstream regulators that mediate the transcription of FBXL7. We found that several consensus upstream regulators are possibly inhibited or activated after PTX treatment in OVSAHO and KURAMOCHI cells, respectively, in the IPA prediction (Figure 5C). Here, FBXL7 is linked to ovarian cancer.